The contribution of this mutation to the acquisition of resistance was confirmed by the efficacy of combination of the MEK inhibitor selumetinib and osimertinib in the cancer cell line established in vitro from this tumor xenograft [22]. The gene discussed is MAP2K7; the disease is neoplasm.